Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label 12-week study of valsartan on LDL subfractions in hypertensive adults with metabolic syndrome
2005-003606-28Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of valsartan in hypertension (HTN) and cardiometabolic risk (CMR), sponsored by Novartis. Started Nov 2005; status: completed.
02
Drugs
valsartan
03
Conditions
hypertension (HTN)cardiometabolic risk (CMR)
Beyond the preview
Go deeper on 2005-003606-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003606-28.